KIT-negative undifferentiated endometrial sarcoma with the amplified epidermal growth factor receptor gene showing a temporary response to imatinib mesylate

Annals of Diagnostic Pathology

Volumn 11, Issue 1, 2007, Pages 49-54

  Mitsuhashi, Tomoko ^a   Nakayama, Masato ^a   Sakurai, Shinji ^b   Fujimura, Masaki ^a   Shimizu, Yoshihiko ^a   Ban, Shinichi ^a   Ogawa, Fumihiro ^a   Hirose, Takanori ^a   Ishihara, Osamu ^a   Shimizu, Michio ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

c kit; EGFR; FISH; KIT; Undifferentiated endometrial sarcoma; Uterus

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; STEM CELL FACTOR;

ABDOMINAL HYSTERECTOMY; ADULT; ANEMIA; ARTICLE; BLADDER; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG WITHDRAWAL; EDEMA; ENDOMETRIUM SARCOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOLECULAR CLONING; PELVIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; SIDE EFFECT; SMOOTH MUSCLE; TUMOR BIOPSY; TUMOR GROWTH; TUMOR VOLUME; UNDIFFERENTIATED ENDOMETRIUM SARCOMA;

ANTINEOPLASTIC AGENTS; BIOPSY; CELL DIFFERENTIATION; DNA, NEOPLASM; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SARCOMA;

EID: 33846208614     PISSN: 10929134     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anndiagpath.2006.03.012     Document Type: Article

References (16)

1. Silverberg S.G., and Kurman R.J. Endometrial stromal tumors. In: Rosai J. (Ed). Tumors of the uterine corpus and gestational trophoblastic disease. Fascicle 3. Atlas of tumor pathology. Third series (1992), Armed Forces Institute of Pathology, Washington, DC 91-111
2. Amant F., Moerman P., and Vergote I. The classification of a uterine sarcoma as ehigh-grade endometrial stromal sarcomaf should be abandoned. Gynecol Oncol 95 (2004) 412-418 ['letter']
3. In: Tavassoli F.A., and Devilee P. (Eds). World Health Organization classification of tumours. Pathology and genetics of the tumours of the breast and the female genital organs (2002), IARC Press, Lyon 432
4. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
5. Henrich M.C., Blanke C.D., Druker B.J., et al. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20 (2002) 1692-1703
6. Kitayama Y., Igarashi H., and Sugimura H. Initial intermittent microwave irradiation for fluorescence in situ hybridization analysis in paraffin-embedded tissue sections of gastrointestinal neoplasia. Lab Invest 80 (2000) 779-781
7. Persons D.L., Borelli K.A., and Hsu P.H. Quantitation of HER-2/neu and c-myc gene amplification in breast carcinoma using fluorescence in situ hybridization. Mod Pathol 10 (1997) 720-727
8. Henrich M.C., Corless C.L., Duensing A., et al. PDGFRα activating mutation in gastrointestinal stromal tumors. Science 299 (2003) 708-710
9. Wasag B., Debiec-Rychter M., Pauwels P., et al. Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site. Mod Pathol 17 (2004) 889-894
10. Chiorean M.V., Guicciardi M.E., Yoon J.H., Bronk S.F., Kaufmanns S.H., and Gores G.J. Imatinib mesylate induces apoptosis in human cholangiocarcinoma cells. Liver Int 24 (2004) 687-695
11. Dobashi Y., Takei N., Suzuki S., et al. Aberration of epidermal growth factor receptor expression in bone and soft-tissue tumors: protein overexpression, gene amplification and activation of downstream molecules. Mod Pathol 17 (2004) 1497-1505
12. Carroll M., Ohno-Jones S., Tamura S., Buchdunger E., Zimmermann J., Lydon N.B., et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 90 (1997) 4947-4952
13. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2 (1996) 561-566
14. Johnson F.M., Saigal B., and Donato N.J. Induction of heparin-binding EGF-like growth factor and activation of EGF receptor in imatinib mesylate-treated squamous carcinoma cells. J Cell Physiol 205 (2005) 218-227
15. Sawada M., Tsuda H., Kimura M., Okamoto S., Kita T., Kasamatsu T., et al. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma. Cancer Sci 11 (2003) 986-991
16. Moinfar F., Gogg-Kamerer M., Sommersacher A., Regitnig P., Man Y.G., Zatloukal K., et al. Endometrial stromal sarcomas frequently express epidermal growth factor receptor (EGFR, HER-1): potential basis for a new therapeutic approach. Am J Surg Pathol 29 (2005) 485-489